Phase 3 N=607 Combining Lesinurad With Allopurinol in Inadequate Responders
Gout
Primary: Proportion of Subjects With an sUA Level That is < 6.0 mg/dL — 0.542; 0.592; 0.279 Proportion of Subjects — p=<0.0001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=8 A Pilot Study of HSCT for Patients With High-risk Hemoglobinopathy Using a Nonmyeloablative Preparative Regimen
Sickle Cell Disease · Thalassemia · Hemoglobinopathies
Primary: Development of GVHD Within 1 Year of BMT — 2 participants
Phase 3 N=598 Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Prostate Cancer
Primary: Overall Survival (OS) Time — 29.73; 28.65 months — p=0.3667
N/A N=70 DAILIES® AquaComfort Plus® Multifocal (MF) - Comparative Assessment of Visual Performance
Presbyopia
Primary: Mean Stereoacuity at Near After 5+/-1 Days of Contact Lens Wear — 40.6; 30.7 arcsec
Phase 2 N=33 Treatment Study of Carnosine Versus Placebo in Gulf War Illness (GWI)
Persian Gulf Syndrome
Primary: Effect of Carnosine Supplementation on Chronic Fatigue Syndrome Severity Scores — -3.8; -2.0 units on a scale — p=0.30
N/A N=80 The Role of Umbilical Cord Thickness in Prediction of Fetal Macrosomia in Patients With Gestational Diabetes Mellitus
Gestational Diabetes
Primary: The Number of Participants Who Were Diagnosed With Fetal Macrosomia (Birth Weight) — 17; 0 participants
Phase 2 N=15 Immunotherapy for Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Blast Phase Chronic Myelogenous Leukemia (BP CML), and Myelodysplastic Syndrome (MDS) Relapse After Allogeneic Transplantation
Leukemia
Primary: Efficacy of GM-CSF and Pegylated Interferon-alpha 2b When Administered to Patients With AML, ALL, Blast Phase CML, and MDS Relapse After Allogeneic Transplantation…
Phase 2 N=87 Rituximab in New Onset Type 1 Diabetes
Type 1 Diabetes Mellitus
Primary: Area Under the Stimulated C-peptide Curve Over the First 2 Hours of a 4-hour Mixed Meal Tolerance Test (MMTT) Administered at 1 Year — 0.58; 0.429 pmol per mL — p=0.05
Phase 3 N=216 Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency
Chronic Kidney Disease · Hyperparathyroidism, Secondary · Vitamin D Deficiency
Primary: Number of Participants in the Intent to Treat Population With Decrease in Plasma Intact Parathyroid Hormone (iPTH) of ≥30% From Pre-treatment Baseline — 5; 49…
Phase 2 N=289 Treatment Based on Molecular Profiling Diagnosis Carcinoma of Unknown Primary Site
Carcinoma
Primary: Overall Survival — 13.43; 7.62 months
N/A N=124 Enhanced Firefighter Rehab Trial: The Role of Aspirin in Preventing Heat Stress Induced Platelet Activation
Heat Stress Disorders
Primary: Platelet Closure Time — 275.5; 207; 95; 90 seconds
N/A N=70 Esmolol or Nitroglycerin Infusion for Blood Pressure Control Prior to Cardiopulmonary Bypass (CPB) in Cardiac Surgery
Hypertension
Primary: Diastolic Blood Pressure Excursions Beyond Predetermined Lower Limits, Normalized Per Hour — 97.9; 45.6 mmHg*min/prebypass hour — p=0.21
Phase 3 N=298 Extension Study of CTAP101-CL-3001 or CTAP101-CL-3002
Chronic Kidney Disease · Hyperparathyroidism, Secondary · Vitamin D Deficiency
Primary: Number of Participants in the Intent to Treat Population With a Mean Reduction in Plasma Intact Parathyroid Hormone (iPTH) of >/= 30% From Baseline Values at End of…
Phase 3 N=213 Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency
Chronic Kidney Disease · Hyperparathyroidism, Secondary · Vitamin D Deficiency
Primary: Number of Participants in the Intent to Treat Population With Decrease in Plasma Intact Parathyroid Hormone (iPTH) of ≥30% From Pre-treatment Baseline Values — 6; 46…
Phase 2 N=31 Gemcitabine, Oxaliplatin and Panitumumab in Kras/B-raf Wild-Type Biliary Track and Gallbladder Cancer
Biliary Tract Cancer · Gallbladder Cancer
Primary: The Number of Participants With Response to GEMOX-Panitumumab (GEMOX-P) in Chemotherapy naïve KRAS/ BRAF Wild Type Stage IV Biliary Tract Cancer Using the Response…